| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tisha R Joy, Charles A McKenzie, Rommel G Tirona, Kelly Summers, Shannon Seney, Subrata Chakrabarti, Neel Malhotra and Melanie D Beaton |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Physicians' Services Incorporate Foundation |
10q2083 |
| Academic Medical Organization of Southwestern Ontario |
F10-002 |
| Program of Experimental Medicine and Department of Medicine Academic (partly) |
|
| Funds from Western University, London, Ontario, Canada (partly) |
|
|
| Corresponding Author |
Dr. Melanie D Beaton, Associate Professor, Department of Medicine, Division of Gastroenterology, London Health Sciences Centre, Western University, 339 Windermere Road, London, Ontario N6A 5A5,
Canada. melanie.beaton@lhsc.on.ca
|
| Key Words |
Sitagliptin; Randomized controlled trial; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Fibrosis; Magnetic resonance imaging; Hepatic steatosis; Insulin resistance; Platelet aggregation |
| Core Tip |
Presently, there is no approved medical therapy for non-alcoholic steatohepatitis (NASH). In this randomized placebo-controlled trial, the effect of sitagliptin on liver fibrosis in patients with NASH after 24 wk was evaluated. There was no significant improvement with the use of sitagliptin on liver fibrosis, total non-alcoholic fatty liver disease activity score or its individual components. Similarly, there were no significant improvements in liver enzymes, adipocytokines, lipid profile, thrombosis parameters, or adipose distribution. There was a strong correlation between hepatic fat % measured using the MRI IDEAL technique and hepatic steatosis on liver biopsy.
|
| Publish Date |
2017-01-05 11:10 |
| Citation |
Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, Malhotra N, Beaton MD. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol 2017; 23(1): 141-150 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i1/141.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i1.141 |
